开发一种人工智能产生的,向血小板类型·威尔布兰德病
Thomas D D Kazmirchuk1,2,3, Jiashu Wang1,2,3, Loredana Bury4
1Department of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Blood advances
|September 12, 2025
概括
一种新的抑制剂,G14,选择性地向了血小板类型·维勒布兰德病 (PT-VWD) 中异常的血小板糖蛋白Iba相互作用. 这一发现为这种罕见的出血障碍提供了针对性治疗和诊断的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板型·威尔布兰德病 (PT-VWD) 是一种罕见的出血疾病,由血小板糖蛋白Ibα (GPIbα) 的功能增益突变引起.
- 这些突变导致GPIbα和·维勒布兰德因子 (VWF) 之间的过活蛋白-蛋白相互作用 (PPI),导致病理性血小板聚合.
- 目前,尽管PT-VWD具有明确的遗传基础,但对PT-VWD没有针对性的治疗方法.
研究的目的:
- 开发一种可选择性向PT-VWD中异常GPIbα-VWF相互作用的类抑制剂.
- 通过体外和体外测试来验证设计的抑制剂的疗效和特异性.
- 探索已识别的抑制剂作为PT-VWD的诊断工具的潜力.
主要方法:
- 利用In Silico蛋白质合成器设计和选10,000个针对突变GPIbα (GPIbαMet239Val) 的和特异性的.
- 通过使用GPIbαGly233Val和Met239Val变体的体外试验,以及PT-VWD患者的体外血小板试验进行功能验证.
- 采用结构建模来预测类抑制剂的结合部位和作用机制.
主要成果:
- 确定了一种抑制剂,G14,证明了GPIbαGly233Val,Met239Val-VWF PPI的强大和选择性抑制.
- 对于突变的GPIbα,G14表现出皮克分子亲和力 (6.6 pM),并选择性地破坏了VWF相互作用,而不影响野生型GPIbα或单独的VWF.
- 活体试验显示,在PT-VWD患者样本中,G14抑制了VWF结合和RISTOCETIN诱导的血小板凝结,对健康对照没有影响.
结论:
- G14代表了与疾病相关的GPIbα-VWF相互作用的高度特异性抑制剂,为向PT-VWD治疗提供了概念验证.
- G14的特异性表明其作为识别PT-VWD的诊断工具的潜在实用性.
- 这项研究强调了人工智能在为特定疾病的PPI设计精密疗法的有效性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Formation of the Platelet Plug
8.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.8K
Structure and Function of Platelets
3.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.0K


